Effects of selective COX-2 inhibitors on the gastric permeability of sucrose: a controlled study with placebo and ibuprofen.
OBJECTIVE
Acute and chronic use of non-steroidal anti-inflammatory drugs can increase gastrointestinal permeability. Celecoxib, which selectively inhibits the enzyme cyclooxygenase-2, is a novel anti-inflammatory drug with minimal gastrointestinal toxic effects while retaining anti-inflammatory efficacy. Our aim was to assess the potential effects of celecoxib on gastric permeability in comparison with placebo and ibuprofen.


METHODS
We conducted a prospective, double-blind, cross-over study.


METHODS
This study is carried out at Marmara University Hospital.


METHODS
Twenty-five healthy subjects entered the study but 19 subjects completed the treatment.


METHODS
Subjects were randomized to celecoxib 100 mg twice daily, ibuprofen 600 mg twice daily or placebo for 7 days in pre-defined sequences. Treatments were separated by a 7 day washout period.


METHODS
Gastric permeability was assessed by measuring urinary excretion of sucrose spectrophotometrically.


RESULTS
Ibuprofen 600 mg twice daily produced greater increases in gastric permeability compared with placebo or celecoxib (geometric mean of urinary sucrose recovery was 59.15, 32.65 and 33.11 mg/h for ibuprofen, placebo and celecoxib, respectively) (P < 0.001). Celecoxib was generally better tolerated than ibuprofen.


CONCLUSIONS
When compared with ibuprofen, celecoxib 100 mg twice daily has no significant effect on gastric mucosa in healthy subjects.
Ekenel
Meltem
M
Department of Internal Medicine, Marmara University Faculty of Medicine, Istanbul, Turkey.
Avşar
Erol
E
Imeryüz
Neşe
N
Yüksel
Meral
M
Haklar
Goncagül
G
Kocakaya
Ozan
O
Tözün
Nurdan
N
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000494:pharmacology*; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D004311:Double-Blind Method; D005753:Gastric Mucosa / Q000378:metabolism; D006801:Humans; D007052:Ibuprofen / Q000009:adverse effects / Q000494:pharmacology; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D008297:Male; D008565:Membrane Proteins; D010539:Permeability; D011446:Prospective Studies; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D013270:Stomach / Q000187:drug effects*; D013395:Sucrose / Q000493:pharmacokinetics* / Q000652:urine; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007527:Isoenzymes; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013395:Sucrose; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib; D007052:Ibuprofen